Startups
Genisphere LLC is the provider of the 3DNA® platform for targeted drug delivery. 3DNA® is a nanoscale, multivalent scaffold made from proprietary, synthetic DNA formed in a flexible, branched structure. 3DNA® nanocarriers are engineered and crosslinked to form a stable architecture while maintaining the biocompatibility of the nucleic acid building blocks, and demonstrate efficacy and safety with a variety of drug cargos across multiple indications. Genisphere's technology is IP-protected and fully customizable to deliver small molecules, biologics, and nucleic acids with precise specificity enabled by multivalent targeting via antibodies, peptides and other molecular entities. Genisphere leverages a collaborative model to advance its 3DNA® drug delivery platform, and seeks additional partnerships with biotechnology and pharmaceutical companies to improve efficacy and reduce toxicity. Genisphere is also advancing its own lead programs based on 3DNA® nanotechnology. Our mission is to expand our collaborative partnerships and utilize our longstanding nanotechnology expertise to enhance the human condition through new 3DNA-based therapeutics. For us, this mission is much more than words on a page. We live this mission every day as we employ the unique characteristics of our flexible platform to support our continuing partnerships and to advance our own lead programs based on 3DNA® nanotechnology.
Overview
Location
United States, Pennsylvania, Hatfield Township
Employees
11-50
Total raised
$13M
Founded date
1997
Funding Rounds 3
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Sep 30, 2015 | Funding round | $4M | |
| Sep 16, 2014 | Funding round | $2M |
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 16, 2014 | Genisphere Closes $2M in Funding | Genisphere LLC, a Hatfield, PA-based provider of targeted drug delivery platform, closed $2m in funding. Backers included existing investors Corporate Fuel Partners, a New York fund. Led by Bob Getts, Chief Science Officer, Genisphere provi... |
| Nov 30, 2012 | Biotech startup developing nanoparticles for cancer treatment and improving accuracy of tests | Lankenau also wants to use the therapeutic delivery to go after cells that cause post cataract surgery eye lesions. Earlier this year, Genisphere and Lankenau initiated a collaboration to develop better tools to diagnose Crohn’s disease and... |
| Biotech startup developing nanoparticles for cancer treatment and improving accuracy of tests | A biotechnology startup is working with Lankenau Institute for Medical Research to develop nanotherapeutics for cancer and eye diseases in the latest in a series of collaborations forged by the suburban Philadelphia company. Genisphere, a H... |
Reviews 0
FAQ about Genisphere
When was Genisphere founded?
Genisphere was founded in 1997.
How much funding has Genisphere raised?
Genisphere has raised $13M in total across 3 funding rounds.
What funding rounds has Genisphere raised?
Parsers VC lists 3 funding rounds of Genisphere, among them a funding round of $4M on Sep 30, 2015 and a funding round of $2M on Sep 16, 2014.
What has the press written about Genisphere?
Parsers VC has collected 4 articles mentioning Genisphere, among them “Genisphere Closes $2M in Funding” (Sep 16, 2014) and “Biotech startup developing nanoparticles for cancer treatment and improving accuracy of tests” (Nov 30, 2012).
Is Genisphere still active?
Yes, Genisphere is active; its latest activity on Parsers VC dates from Nov 1, 2017.